Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine

Japanese pharmaceutical Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint.

The drug, a protease inhibitor known as ensitrelvir, was administered daily for five days and led to a significant reduction in symptoms such as stuffy or runny nose, sore throat, cough, feeling hot or feverish, and low energy or tiredness within 72 hours of its onset, the company announced Wednesday. A total of 1,821 mostly vaccinated patients from Japan, South Korea and Vietnam were enrolled in the study.

The median time for patients to experience relief in five Covid-19 symptoms was significantly reduced in the cohort that was treated with the low dose of ensitrelvir (the dose level submitted for approval in Japan) compared to placebo: 167.9 hours versus 192.2. No significant adverse effects were noted, the company said.

Meanwhile, the study also hit its secondary endpoint —…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*